4D Molecular Therapeutics, Inc. (FDMT) vs Faeth Therapeutics, Inc. (FTH)
A side-by-side comparison of 4D Molecular Therapeutics, Inc. and Faeth Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FDMT
4D Molecular Therapeutics, Inc.
$12.56HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
FTH
Faeth Therapeutics, Inc.
$26.89HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — FDMT vs FTH
growth of $100 · dividends reinvested · last 6yFDMT -74.2% (-20.2%/yr)FTH -92.8% (-35.5%/yr)FDMT compounded faster over this window
FDMT FTH
FDMT vs FTH: by the numbers
- •FTH is the larger company ($693M vs $657M market cap).
- •Both run net losses; FTH's is the smaller (0.00% vs -194.74% net margin).
Metrics side by side
Valuation
| Metric | FDMT | FTH |
|---|---|---|
| P/S ratio | 7.14 | N/A |
| P/B ratio | 1.61 | 4.01 |
Profitability
| Metric | FDMT | FTH |
|---|---|---|
| Gross margin | 91.05% | 0.00% |
| Operating margin | -187.24% | 0.00% |
| Net margin | -194.74% | 0.00% |
| ROE | -43.95% | -113.05% |
| ROIC | -44.30% | -110.62% |
Growth (annualized)
| Metric | FDMT | FTH |
|---|---|---|
| Revenue CAGR (5Y) | 31.93% | N/A |
| Total return CAGR (5Y) | -13.08% | -31.75% |
Frequently asked
- How have FDMT and FTH total returns compared?
- Over the past 5 years, FDMT delivered -13.08% and FTH delivered -31.75% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
4D Molecular Therapeutics ROEFaeth Therapeutics ROE4D Molecular Therapeutics operating marginFaeth Therapeutics operating margin4D Molecular Therapeutics revenue growthFaeth Therapeutics revenue growth4D Molecular Therapeutics free cash flowFaeth Therapeutics free cash flow
4D Molecular Therapeutics & Faeth Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.